{"id":"W2148643283","doi":"10.1056/nejmoa1207506","title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4574,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Genentech; Cilag; Astellas Pharma; Teva Pharmaceutical Industries; Eisai; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Pfizer; Active Biotech; Celgene; Astellas Pharma Global Development; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen receptor; Oncology; Overall survival; Internal medicine; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}